. "2 RECENT TRENDS IN SUPPORT FOR BIOMEDICAL RESEARCH AND DEVELOPMENT." Sources of Medical Technology Universities and Industry. Washington, DC: The National Academies Press, 1995.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Sources of Medical Technology: Universities and Industry
TABLE 2-4 Biotechnology Medicines or Vaccines Approved by the Food and Drug Administration, 1993
Product
Indications
Company
Year Approved
Beta interferon
Multiple sclerosis
Chiron
1993
DNAse
Cystic fibrosis
Genentech
1993
Factor VIII
Hemophilia
Genentech, Genetics Institute
1993
IL-2
Renal cell cancer
Chiron
1992
Indium-111-labeled antibody
Cancer imaging
Cytogen
1992
Aglucerase
Gaucher's disease
Genzyme
1991
G-CSF
Adjunct to chemotherapy
Amgen
1991
GM-CSF
Bone marrow transplant
Immunex
1991
Hyaluronic acid
Ophthalmic surgery
Genzyme
1991
CMV immune globulin
Prevention of rejection in organ transplants
MedImmune
1990
Gamma interferon
Chronic granulomatous disease
Genentech
1990
PEG-adenosine deaminase
Immune deficiency
Enzon
1990
t-PA
Myocardial infarction, pulmonary embolism
Genentech
1990
Erythropoietin
Anemia associated with renal failure, AIDS, cancer
Amgen
1989
Hepatitis B antigens
Diagnosis
Biogen
1987
Alpha interferon
Cancer, genital warts, hepatitis
Biogen, Genentech
1986
Hepatitis B vaccine
Prevention
Biogen, Chiron
1986
Human growth hormone
Deficiency
Genentech
1985
Human insulin
Type I diabetes
Genentech
1982
SOURCE: "Datawatch: Biotechnology and Innovation Progress Reports," in Health Affairs, Summer, 1994.
